Mobile

A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 dia...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004881-34

A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 diabetes

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The first primary objective is to assess the antidiabetic effect of rimonabant (HbA1C) over a period of 6 months when prescribed in treatment-naïve type 2 diabetes patients.

Critère d'inclusion

  • Patients with Type 2 diabetes not treated by a pharmacological agent

Liens